Kura Oncology announced promising Phase 1a data for darlifarnib combined with adagrasib, showing objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in colorectal cancer patients naive to KRAS inhibitors. The drug demonstrated activity in both KRAS inhibitor-naïve and pretreated patients, supporting its potential as a foundational combination therapy across various KRAS-mutant cancers. Kura plans to expand development through a new platform study, starting with a combination of darlifarnib and daraxonrasib in pancreatic cancer, expected to enter Phase 1a trials in early 2027. This strategy aims to improve treatment outcomes by combining darlifarnib with multiple targeted therapies across different cancer types.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
Amaroq Ltd. reported strong underground drilling results at the Nalunaq Gold Mine in Greenland, with high-grade gold intersections averaging 42.8 g/t Au, including some assays above 130 g/t Au. These results reinforce confidence in the mine's near- a...
